Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.38 |
| ▸ | HTR6 | P50406 | 9/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131648 | 1.00 | HTR2A (0.38) | HTR2AHTR6POLBLMNAGAA | |
| SCHEMBL1131175 | 0.83 | ALDH1A1 (0.48) | HTR2AHTR6POLBLMNAGAA | |
| SCHEMBL1131174 | 0.83 | ALDH1A1 (0.48) | HTR2AHTR6POLBLMNAGAA | |
| SCHEMBL13083251 | 0.81 | LMNA (0.39) | POLBLMNAGAASMN1; SMN2CYP3A4 | |
| SCHEMBL1131679 | 0.78 | RECQL (0.42) | POLBNPC1RAB9ARECQLALDH1A1 | |
| SCHEMBL1131052 | 0.75 | GAA (0.43) | HTR2AHTR6LMNAGAAHTR2C | |
| SCHEMBL1131049 | 0.75 | GAA (0.43) | HTR2AHTR6LMNAGAAHTR2C | |
| SCHEMBL4185071 | 0.71 | RAB9A (0.66) | POLBLMNANPC1RAB9ARECQL | |
| SCHEMBL31194220 | 0.71 | RAB9A (0.66) | POLBLMNANPC1RAB9ARECQL | |
| SCHEMBL28504880 | 0.70 | NPC1 (0.47) | POLBLMNANPC1RAB9ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-1664035-B1 | 2,4 DI(HETERO)-ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2266977-A1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1664035-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026158-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | ZAP70, SYK, BTK | HTR2A 1577/4885HTR6 1928/4885POLB 1284/4885 |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | ZAP70, SYK, BTK | HTR2A 1913/4885HTR6 2195/4885POLB 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.